REFERENCES

Introduction


Hamoen EHJ, de Rooij M, Witjes JA, Barentsz J. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for prostate cancer detection with multiparametric magnetic resonance imaging: a diagnostic meta-analysis. European Urology 2014 (In press).

Section I: Clinical Considerations and Technical Specifications


Park KK, Lee SH, Lim BJ, Kim JH, Chung BH. The effects of the period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int 2010;106:1146-1151


Haider MA, krieger A, Elliot C, Da Rosa MR, Milot L. Prostate imaging: evaluation of reusable two-channel endorectal receiver coil for MR imaging at 1.5T. Radiology 2014;270:556-565


Section II: Normal Anatomy and Benign Findings
McNeal JE. The Zonal anatomy of the prostate. The Prostate 1981;2:35-49


Engelhard K, Hollenback HP, Deimiing M, Kerckel M, Riedi C. Combination of signal intensity measurements of lesions in the peripheral zone of prostate with MRI and serum PSA level for differentiating benign disease from prostate cancer. Eur Radiol 2000;10(12):1947-1953

Section III: Assessment and Reporting
Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994 Feb 2;271(5):368-74.


Tamada T, Kanomata N, Sone T, Jo Y, Miyaji Y, Higashi H, et al. High b value (2,000 s/mm2) diffusion-weighted magnetic resonance imaging in prostate cancer at 3 Tesla: comparison with 1,000 s/mm2 for tumor conspicuity and discrimination of aggressiveness. PLOS ONE 2014;9(5):e96619.


Section V: Staging


Sector Map Credit: